Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study

Journal of Neurology

Volumn 264, Issue 2, 2017, Pages 268-276

  Planté Bordeneuve, Violaine ^a,b   Gorram, Farida ^a,b   Salhi, Hayet ^a,b   Nordine, Tarik ^a,b   Ayache, Samar S ^a,b   Le Corvoisier, Philippe ^a   Azoulay, Daniel ^a   Feray, Cyrille ^a   Damy, Thibaud ^a,b   Lefaucheur, Jean Pascal ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b FACULTÉ DE MÉDECINE   (France)

Author keywords

Amyloidosis; Genetics; Longitudinal study; Neurophysiology; Peripheral neuropathy; Response; Small nerve fibres; Transthyretin; Treatment

Indexed keywords

PREALBUMIN; TAFAMIDIS; BENZOXAZOLE DERIVATIVE; HEMATOLOGIC AGENT;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; DISEASE COURSE; DRUG TOLERABILITY; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; MENTAL DETERIORATION; NERVE FIBER; PRIORITY JOURNAL; WALKING; AMYLOID NEUROPATHIES, FAMILIAL; DRUG EFFECTS; GENETICS; MIDDLE AGED; NERVE CONDUCTION; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID NEUROPATHIES, FAMILIAL; BENZOXAZOLES; BODY MASS INDEX; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC AGENTS; HUMANS; MALE; MIDDLE AGED; NEURAL CONDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84996497534     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-016-8337-3     Document Type: Article

References (24)

1. Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M et al (2015) Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 66:2451–2466
2. Planté-Bordeneuve V, Said G (2011) Familial amyloid polyneuropathy. Lancet Neurol 10:1086–1097
3. Lefaucheur JP, Ng Wing Tin S, Kerschen P, Damy T, Planté-Bordeneuve V (2013) Neurophysiological markers of small fibre neuropathy in TTR-FAP mutation carriers. J Neurol 260:1497–1503
4. Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S et al (1991) Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 40:242–246
5. Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O et al (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341:1113–1116
6. Benson MD (2013) Liver transplantation and transthyretin amyloidosis. Muscle Nerve 47:157–162
7. Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR et al (2015) Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 99:1847–1854
8. Tasaki M, Ueda M, Obayashi K, Koike H, Kitagawa K, Ogi Y et al (2013) Effect of age and sex differences on wild-type transthyretin amyloid formation in familial amyloidotic polyneuropathy: a proteomic approach. Int J Cardiol 170:69–74
9. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW (2012) The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 421:185–203
10. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P et al (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79:785–792
11. Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB et al (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 260:2802–2814
12. Lozeron P, Théaudin M, Mincheva Z, Ducot B, Lacroix C, Adams D et al (2013) Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol 20:1539–1545
13. Merlini G, Planté-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S et al (2013) Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res 6:1011–1020
14. Dyck PJ, Davies JL, Litchy WJ, O’Brien PC (1997) Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 49:229–239
15. Steen L, Ek B (1983) Familial amyloidosis with polyneuropathy. A long-term follow-up of 21 patients with special reference to gastrointestinal symptoms. Acta Med Scand 214:387–397
16. Yates JW, Chalmer B, McKegney FP (1980) Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45:2220–2224
17. Lefaucheur JP, Wahab A, Planté-Bordeneuve V, Sène D, Ménard-Lefaucheur I, Rouie D et al (2015) Diagnosis of small fiber neuropathy: a comparative study of five neurophysiological tests. Neurophysiol Clin 45:445–455
18. Ng Wing Tin S, Planté-Bordeneuve V, Salhi H, Goujon C, Damy T, Lefaucheur JP (2015) Characterization of pain in familial amyloid polyneuropathy. J Pain 16:1106–1114
19. Mariani LL, Lozeron P, Théaudin M, Mincheva Z, Signate A, Ducot B et al (2015) French familial amyloid polyneuropathies network (CORNAMYL) study group. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 78:901–916
20. Ando Y, Sekijima Y, Obayashi K, Yamashita T, Ueda M, Misumi Y et al (2016) Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Varl30Met: a phase III, open-label study. J Neurol Sci 362:266–271
21. Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M et al (2016) Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol 263:916–924
22. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T et al (2013) Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310:2658–2667
23. Adams D, Coelho T, Obici L, Merlini G, Mincheva Z, Suanprasert N et al (2015) Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology 85:675–682
24. Suanprasert N, Berk JL, Benson MD, Dyck PJ, Klein CJ, Gollob JA et al (2014) Retrospective study of a TTR FAP cohort to modify NIS + 7 for therapeutic trials. J Neurol Sci 344:121–128